Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer

Clinical Breast Cancer

Volumn 7, Issue 3, 2006, Pages 262-269

  Amat, Sophie ^a   Mouret Reynier, Marie Ange ^a,b   Penault Llorca, Frédérique ^a,b,c   Leheurteur, Marianne ^a   Delva, Rémi ^d   Coudert, Bruno ^e   Leduc, Bernard ^f   Dauplat, Jacques ^a,b   Curé, Hervé ^a,b,c,g,h   Chollet, Philippe ^a,b,c,g  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c INSERM   (France)

^d CENTRE PAUL PAPIN   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f Centre Hospitalier General   (France)

^g CIC 501   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Hormonal therapy; Response; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; NAVELBINE; PIRARUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MYALGIA; NEUTROPENIA; ONYCHOLYSIS; PARESTHESIA; PHASE 2 CLINICAL TRIAL; STOMACH PAIN; THROMBOCYTOPENIA;

EID: 33749028707     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.039     Document Type: Article

References (41)

1. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998; 25:3-12.
2. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18:1558-1569.
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940-1948.
4. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991; 2:347-354.
5. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A:645-652.
6. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13:547-552.
7. van der Hage JA, van de Velde CJ, Juhen JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-4237.
8. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
9. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. J Clin Oncol 2001; 19:1707-1715.
10. Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide, (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:25a (Abstract #137).
11. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. TAX 306 Study Group. J Clin Oncol 2003; 21:968-975.
12. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C974/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-1439.
13. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
14. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphemide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21:36a (Abstract #141).
15. Trudeau M, Sinclair SE, Clemons M. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review Breast Cancer Disease Site Group. Cancer Treat Rev 2005; 31:283-302.
16. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-5551.
17. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643-2655.
18. O'Leary J, Volm M, Wasserheit C, et al. Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology (Williston Park) 1998; 12(1 suppl. 1):23-27.
19. Costa SD, von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 1999; 26:24-31.
20. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88:1339-1345.
21. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33:862-866.
22. Misset JL, di Palma M, Delgado M, et al. Adjuvant treatment of nodepositive breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after 16-year median follow-up duration. J Clin Oncol 1996; 14:1136-1145.
23. Belembaogo E, Feillel V, Chollet P, et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 1992; 28A:896-900.
24. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-1252.
25. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
26. Jackisch C, von Minckwitz G, Eidtmann H, et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 2002; 3:276-280.
27. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676-2685.
28. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 1998; 25(2 suppl 3):31-35.
29. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21:4165-4174.
30. Sobin LH, Wittekind CH. UICC - TNM Classification of Malignant Tumours. 5th ed. New York, NY: Wiley-Liss; 1997.
31. Elston CW, Ellis IO. Pathological Prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-410.
32. Ferriere JP, Assier I, Cure H, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21:117-120.
33. Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
34. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16:223-228.
35. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180:297-306.
36. Romieu G, Tubiana-Hulin M, Fumoleau P, et al. A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/Taxol® (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC). Ann Oncol 2002; 13(suppl 5):33 (Abstract #118).
37. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophasphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24:2019-2027.
38. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037-1044.
39. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86:1041-1046.
40. Miller KD, McCaskill-Stevens, W Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17:3033-3037.
41. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3(suppl 2):S69-S74.